Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sorbinil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 known ✓ | P15121 | 1/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | AKR1A1 | P14550 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sorbinil SCHEMBL17223865 | 1.00 | AKR1B10 (1.00) | AKR1B10MAPTAKR1A1AKR1B1 | |
| Sorbinil SCHEMBL9790028 | 1.00 | AKR1B10 (1.00) | AKR1B10MAPTAKR1A1AKR1B1 | |
| Sorbinil SCHEMBL29599732 | 1.00 | AKR1B10 (1.00) | AKR1B10MAPTAKR1A1AKR1B1 | |
| Sorbinil SCHEMBL48877 | 1.00 | AKR1B10 (1.00) | AKR1B10MAPTAKR1A1AKR1B1 | |
| SCHEMBL12620675 | 0.89 | AKR1B10 (0.80) | AKR1B10MAPTAKR1A1AKR1B1 | |
| SCHEMBL7867894 | 0.89 | AKR1B10 (0.80) | AKR1B10MAPTAKR1A1AKR1B1 | |
| Sorbinil SCHEMBL11088391 | 0.88 | AKR1B10 (0.78) | AKR1B10MAPTAKR1A1AKR1B1 | |
| Sorbinil SCHEMBL11097273 | 0.88 | AKR1B1 (0.78) | AKR1B10MAPTAKR1A1AKR1B1 | |
| SCHEMBL3439473 | 0.86 | AKR1B1 (0.76) | AKR1B10MAPTAKR1A1AKR1B1 | |
| SCHEMBL9824214 | 0.86 | AKR1B1 (0.76) | AKR1B10MAPTAKR1A1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0111387-B1 | REGENERATION OF 6-FLUORO-4-CHROMANONE FROM BY-PRODUCTS IN THE SYNTHESIS OF SORBINIL | PFIZER INC. (US) | 1986-04-09 | — | — | EP | claimed |
| EP-0175312-A2 | Process for preparing optically active hydantoins | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1986-03-26 | — | — | EP | claimed |
| EP-0111387-A1 | Regeneration of 6-fluoro-4-chromanone from by-products in the synthesis of sorbinil | PFIZER INC. (US) | 1984-06-20 | — | — | EP | claimed |
| US-4431828-A | Regeneration of 6-fluoro-4-chromanone from by-products in the synthesis of sorbinil | PFIZER INC. (US) | 1984-02-14 | — | — | US | claimed |
| US-4177282-A | ANITDIABETIC | PFIZER INC. (US) | 1979-12-04 | — | — | US | claimed |
| US-4147795-A | ENZYME INHIBITORS | PFIZER INC. (US) | 1979-04-03 | — | — | US | claimed |
| US-4130714-A | SPIRO CHROMANS OR THIOCHROMANS | PFIZER INC. (US) | 1978-12-19 | — | — | US | claimed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| US-8158667-B2 | Topical treatment of cataracts in dogs | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2012-04-17 | — | — | US | disclosed |
| WO-2010065024-A1 | TOPICAL TREATMENT OF CATARACTS IN DOGS | KADOR PETER F (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20090082415-A1 | Topical treatment of cataracts in dogs | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2009-03-26 | — | — | US | disclosed |
| US-4177282-A | ANITDIABETIC | PFIZER INC. (US) | 1979-12-04 | — | — | US | disclosed |
| US-4147795-A | ENZYME INHIBITORS | PFIZER INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4147795-A | ENZYME INHIBITORS | PFIZER INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4130714-A | SPIRO CHROMANS OR THIOCHROMANS | PFIZER INC. (US) | 1978-12-19 | — | — | US | disclosed |
| US-4130714-A | SPIRO CHROMANS OR THIOCHROMANS | PFIZER INC. (US) | 1978-12-19 | — | — | US | disclosed |
| US-4117230-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1978-09-26 | — | — | US | disclosed |
| US-4117230-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | AKR1B1 1566/4885AKR1B10 1719/4885MAPT 898/4885 |
| US-20090082415-A1 | Topical treatment of cataracts in dogs | AKR1A1, AKR1B1, AKR1C1 | AKR1B1 2/4885AKR1B10 9/4885MAPT 758/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | AKR1B1 1566/4885AKR1B10 1719/4885MAPT 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.